Dupixent Products-Liability MDL 3180 is the federal court coordination for Dupixent injury claims, and you read it through master docket 3:26-md-03180-ZNQ-JBD in New Jersey. An MDL, or multidistrict litigation, moves similar federal lawsuits to one judge for shared pretrial work. The U.S.
Judicial Panel on Multidistrict Litigation says in the transfer order that it centralized the cases on June 4, 2026 before Judge Zahid N. Quraishi in the District of New Jersey. plaintiffs allege Dupixent caused or accelerated cutaneous T-cell lymphoma and bring failure-to-warn claims against Regeneron, Sanofi-Aventis U.S. and Genzyme.
Table of Contents
- What cases belong in MDL 3180
- How do you pull the correct docket
- Where do new orders and hearings appear
- How do you check claimed safety developments
What cases belong in MDL 3180
The core claim involves cutaneous T-cell lymphoma, including mycosis fungoides and Sézary syndrome, after Dupixent, or dupilumab, use. Defendants named in the litigation update are Regeneron, Sanofi-Aventis U.S.
and Genzyme. The group was small and growing in fall 2026. A court transfer record styled the lead case as 3:26-md-03180-ZNQ-JBD, short form 26-md-3180, for coordinated pretrial proceedings.
How do you pull the correct docket
Start with the national PACER Case Locator to confirm court, case number and parties, then run the District of New Jersey docket report. The Administrative Office of the U.S.
Courts explains in the PACER FAQ that the Locator refreshes nightly. Use this sequence: Single-plaintiff transfer paperwork can look like progress when it only moves a case to New Jersey. The master docket shows what applies across cases.
- Search "3180" or "In re: Dupixent" in the Case Locator
- Open 3:26-md-03180-ZNQ-JBD, not a single plaintiff's original case
- Run the full docket report for orders, notices and joint reports
- Check party names before saving a filing as an MDL-wide ruling
Where do new orders and hearings appear
Check Judge Quraishi's District of New Jersey page and the master-docket entries in PACER for scheduled appearances, case-management orders and joint status reports. The U.S. District Court for the District of New Jersey posts that schedule material on the judge's page.
Read newest entries first, then work backward to the related order. Case-management orders set deadlines, appointment of leadership counsel, forms for short-form complaints and rules for direct filing. Joint reports often preview disputes before the judge rules. A plaintiff filing, defense filing and judge order are three different weights.
How do you check claimed safety developments
The U.S. Food and Drug Administration says in its safety-signal index that it publishes quarterly Adverse Event Monitoring System reports on new safety information or potential signals of serious risk.
The October–December 2024 table listed Dupixent/dupilumab with cutaneous T-cell lymphoma as a potential signal, with FDA evaluating possible regulatory action. Treat that signal as an early warning, not proof of causation. The Dupixent label's Warnings section, last revised April 2026, still listed no lymphoma warning and the drug was not recalled.